Differential Response to Methylphenidate in Inattentive and Combined Subtype ADHD
Susan H Beery1, Herbert C Quay2, William E Pelham3
11 Lycoming College, Williamsport, PA, USA.
Journal of Attention Disorders
|January 4, 2013
Summary
Methylphenidate (MPH) effectively improved behaviors like interrupting and compliance in hyperactive boys with ADHD. However, it showed minimal impact on core attention and interaction deficits in boys with predominantly inattentive ADHD.
Area of Science:
- Child and Adolescent Psychiatry
- Neurodevelopmental Disorders
- Pharmacological Interventions
Background:
- Attention-Deficit/Hyperactivity Disorder (ADHD) presents with diverse symptom profiles, including predominantly hyperactive-impulsive (HI) and inattentive (I) subtypes.
- Methylphenidate (MPH) is a common stimulant medication used to manage ADHD symptoms.
- Objective assessment of MPH response in ecologically valid settings is crucial for optimizing treatment.
Purpose of the Study:
- To evaluate the differential response to methylphenidate (MPH) in boys with ADHD, comparing those with high hyperactivity-impulsivity (ADHD/HI) to those with predominantly inattentive symptoms (ADHD/I).
- To assess MPH efficacy using direct observation of behaviors within a structured, real-world setting (Summer Treatment Program).
Main Methods:
- A double-blind, placebo-controlled study involving 63 boys (ages 7-13) with ADHD.
- Participants received a standardized dose of MPH (.3 mg/kg) or placebo.
- Behavioral responses were measured through direct observation of problem behaviors and individualized goals, with medication effect sizes calculated for each behavior.
Main Results:
- Boys with ADHD/HI demonstrated significant positive responses to MPH, with larger effect sizes observed for behaviors such as interrupting, verbal abuse, compliance, teasing, and goal achievement.
- Boys with ADHD/I showed minimal medication effect sizes (ds < .20) for key deficits including attention to activities, peer interactions, and academic task completion.
- Differential treatment effects suggest varying MPH efficacy across ADHD symptom presentations.
Conclusions:
- Methylphenidate (MPH) appears more effective in ameliorating externalizing behaviors in ADHD/HI than core inattentive symptoms in ADHD/I.
- There is a critical need for systematic medication assessments that quantify MPH response in ecologically valid domains relevant to functional impairment in ADHD/I.
- Further research should explore alternative or adjunctive treatments for the inattentive symptom cluster in ADHD/I.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...